A citation-based method for searching scientific literature

Athira K V, Arathy S Mohan, Sumana Chakravarty. Brain Res Bull 2020
Times Cited: 9







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
361
44

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
44

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
742
33


Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
408
22


A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.
Elias Dakwar, Edward V Nunes, Carl L Hart, Richard W Foltin, Sanjay J Mathew, Kenneth M Carpenter, C J Jean Choi, Cale N Basaraba, Martina Pavlicova, Frances R Levin. Am J Psychiatry 2019
51
22

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.
Chadi G Abdallah, Lynnette A Averill, Ralitza Gueorguieva, Selin Goktas, Prerana Purohit, Mohini Ranganathan, Mohamed Sherif, Kyung-Heup Ahn, Deepak Cyril D'Souza, Richard Formica,[...]. Neuropsychopharmacology 2020
68
22

The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
Roger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, Amna Majeed, Prakash S Masand, Hartej Gill, Nelson B Rodrigues, Orly Lipsitz, Alexandria C Coles, Yena Lee,[...]. J Affect Disord 2020
55
22

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
839
22

Synaptic dysfunction in depression: potential therapeutic targets.
Ronald S Duman, George K Aghajanian. Science 2012
799
22

Genome-wide association study and polygenic risk score analysis of esketamine treatment response.
Qingqin S Li, Ewa Wajs, Rachel Ochs-Ross, Jaskaran Singh, Wayne C Drevets. Sci Rep 2020
13
22

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Chadi G Abdallah, Gerard Sanacora, Ronald S Duman, John H Krystal. Annu Rev Med 2015
238
22

A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Andrew D Krystal, Diego A Pizzagalli, Moria Smoski, Sanjay J Mathew, John Nurnberger, Sarah H Lisanby, Dan Iosifescu, James W Murrough, Hongqiu Yang, Richard D Weiner,[...]. Nat Med 2020
73
22


Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew A Boehm, Juan L Gomez, Oscar Solís, Marta Sánchez-Soto, Patrick J Morris, Ida Fredriksson, Craig J Thomas,[...]. Mol Psychiatry 2021
56
22

mTOR in Brain Physiology and Pathologies.
Joël Bockaert, Philippe Marin. Physiol Rev 2015
206
22

Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice.
Xiao-Long Liu, Liu Luo, Rong-Hao Mu, Bin-Bin Liu, Di Geng, Qing Liu, Li-Tao Yi. Sci Rep 2015
67
22

The role of mTOR in depression and antidepressant responses.
Helena M Abelaira, Gislaine Z Réus, Morgana V Neotti, João Quevedo. Life Sci 2014
116
22

Hippocampal mTOR signaling is required for the antidepressant effects of paroxetine.
Dawei Xu, Yuyu Sun, Chengniu Wang, Hao Wang, Yingjie Wang, Wei Zhao, Guofeng Bao, Fei Wang, Zhiming Cui, Bo Jiang. Neuropharmacology 2018
34
22

The role of eEF2 kinase in the rapid antidepressant actions of ketamine.
Kanzo Suzuki, Lisa M Monteggia. Adv Pharmacol 2020
23
22

Molecular neurobiology of mTOR.
Katarzyna Switon, Katarzyna Kotulska, Aleksandra Janusz-Kaminska, Justyna Zmorzynska, Jacek Jaworski. Neuroscience 2017
211
22

Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation.
Taro Kato, Santosh Pothula, Rong-Jian Liu, Catharine H Duman, Rosemarie Terwilliger, George P Vlasuk, Eddine Saiah, Seung Hahm, Ronald S Duman. J Clin Invest 2019
41
22

Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.
Plinio C Casarotto, Mykhailo Girych, Senem M Fred, Vera Kovaleva, Rafael Moliner, Giray Enkavi, Caroline Biojone, Cecilia Cannarozzo, Madhusmita Pryiadrashini Sahu, Katja Kaurinkoski,[...]. Cell 2021
142
22

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.
Courtney S Jernigan, Dharmendra B Goswami, Mark C Austin, Abiye H Iyo, Agata Chandran, Craig A Stockmeier, Beata Karolewicz. Prog Neuropsychopharmacol Biol Psychiatry 2011
273
22

New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.
Zuleide M Ignácio, Gislaine Z Réus, Camila O Arent, Helena M Abelaira, Meagan R Pitcher, João Quevedo. Br J Clin Pharmacol 2016
81
22

Perisynaptic astrocytes as a potential target for novel antidepressant drugs.
Marcos E Frizzo, Yukihiro Ohno. J Pharmacol Sci 2021
8
25

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Yan Yang, Yihui Cui, Kangning Sang, Yiyan Dong, Zheyi Ni, Shuangshuang Ma, Hailan Hu. Nature 2018
390
22

Astrocytes in rapid ketamine antidepressant action.
Matjaž Stenovec, Baoman Li, Alexei Verkhratsky, Robert Zorec. Neuropharmacology 2020
17
22


Circuits and functions of the lateral habenula in health and in disease.
Hailan Hu, Yihui Cui, Yan Yang. Nat Rev Neurosci 2020
124
22

Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.
Steven J Shabel, Christophe D Proulx, Joaquin Piriz, Roberto Malinow. Science 2014
217
22

PI3K/AKT/GSK3β/CRMP-2-mediated neuroplasticity in depression induced by stress.
Zuotian Wu, Gaohua Wang, Yanyan Wei, Ling Xiao, Huiling Wang. Neuroreport 2018
27
22

Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial.
Gholamreza Kheirabadi, Maryam Vafaie, Dorna Kheirabadi, Zahra Mirlouhi, Rasam Hajiannasab. Adv Biomed Res 2019
9
11

Rapid antidepressant effect of S-ketamine in schizophrenia.
Lucie Bartova, Konstantinos Papageorgiou, Ivan Milenkovic, Markus Dold, Ana Weidenauer, Matthaeus Willeit, Dietmar Winkler, Siegfried Kasper. Eur Neuropsychopharmacol 2018
5
20

A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.
Yena Lee, Kahlood Syeda, Nadia A Maruschak, Danielle S Cha, Rodrigo B Mansur, Ida K Wium-Andersen, Hanna O Woldeyohannes, Joshua D Rosenblat, Roger S McIntyre. J Clin Psychopharmacol 2016
45
11


Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo.
A Meneguz, S Fortuna, P Lorenzini, M T Volpe. Exp Toxicol Pathol 1999
34
11

Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion.
Steven J Pennybaker, David A Luckenbaugh, Lawrence T Park, Craig A Marquardt, Carlos A Zarate. Biol Psychiatry 2017
11
11

Side-effects associated with ketamine use in depression: a systematic review.
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker, Colleen K Loo. Lancet Psychiatry 2018
211
11

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Ewa Wajs, Leah Aluisio, Richard Holder, Ella J Daly, Rosanne Lane, Pilar Lim, Joyce E George, Randall L Morrison, Gerard Sanacora, Allan H Young,[...]. J Clin Psychiatry 2020
91
11

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
301
11

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Stuart A Montgomery, Hans-Jürgen Möller. Int Clin Psychopharmacol 2009
81
11

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
A K Malhotra, D A Pinals, C M Adler, I Elman, A Clifton, D Pickar, A Breier. Neuropsychopharmacology 1997
499
11

ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
Sanjay J Mathew, Samuel T Wilkinson, Murat Altinay, Ali Asghar-Ali, Lee C Chang, Katherine A Collins, Roman M Dale, Bo Hu, Kamini Krishnan, Charles H Kellner,[...]. Contemp Clin Trials 2019
19
11


Disruptive treatments in psychiatry.
Eduard Vieta. Rev Psiquiatr Salud Ment (Engl Ed) 2020
6
16

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
Eric W Lumsden, Timothy A Troppoli, Scott J Myers, Panos Zanos, Yasco Aracava, Jan Kehr, Jacqueline Lovett, Sukhan Kim, Fu-Hua Wang, Staffan Schmidt,[...]. Proc Natl Acad Sci U S A 2019
78
11




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.